Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo The fda evaluated libtayo under priority review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions. Review important safety info & full prescribing information including med guide. In a significant step forward for skin cancer management, the u.s Rhapsido (remibrutinib) is approved to treat chronic spontaneous urticaria resistant to antihistamine treatment.
OPEN
